JAK Inhibitors in Solid Organ Transplantation.
Janus kinase inhibitors
heart transplantation
immunosuppressive agents
kidney transplantation
liver transplantation
lung transplantation
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
04
04
2023
accepted:
24
07
2023
medline:
10
11
2023
pubmed:
28
7
2023
entrez:
27
7
2023
Statut:
ppublish
Résumé
Janus kinase (JAK) inhibitors are a novel group of immunosuppressive drugs approved to treat certain rheumatic and allergic disorders; however, their efficacy in the regulation of alloimmune responses after solid organ transplantation has not yet been elucidated. In the present review, we have summarized the results of in vitro, in vivo, experimental, and clinical trial studies about the efficacy and safety of JAK inhibitors in improving allograft survival in solid organ transplantations, including kidney, heart, lung, and liver transplants. Moreover, reports on administering JAK inhibitors to steroid-resistant patients with graft versus host disease (GvHD) after solid organ transplantation have been reviewed. Overall findings are suggestive of a beneficial role for JAK inhibitors in organ transplantation: for example, they have been shown to improve allograft function, reduce the rate and score of acute rejection, downregulate the expression of proinflammatory cytokines and adhesion molecules, and decrease oxidative stress. However, the adverse effects of these drugs, in particular bone marrow suppression and infection, remain an obstacle.
Substances chimiques
Janus Kinase Inhibitors
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1330-1343Informations de copyright
© 2023, The American College of Clinical Pharmacology.
Références
Racusen LC, Regele H. The pathology of chronic allograft dysfunction. Kidney Int. 2010;78:S27-S32.
Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(8):1281-1283.
Moore CA, Iasella CJ, Venkataramanan R, et al. Janus kinase inhibition for immunosuppression in solid organ transplantation: is there a role in complex immunologic challenges? Hum Immunol. 2017;78(2):64-71.
Zhang Y, Ruiz P. Solid organ transplant-associated acute graft-versus-host disease. Arch Pathol Lab Med. 2010;134(8):1220-1224.
Qureshy Z, Johnson DE, Grandis JR. Targeting the JAK/STAT pathway in solid tumors. J Cancer Metastasis Treat. 2020;6:27.
Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18(11):102390.
Brosius III FC, He JC. JAK inhibition and progressive kidney disease. Curr Opin Nephrol Hypertens. 2015;24(1):88.
Baan CC, Kannegieter NM, Felipe CR, Silva Jr HT. Targeting JAK/STAT signaling to prevent rejection after kidney transplantation: a reappraisal. Transplantation. 2016;100(9):1833-1839.
Byrne M, Savani B, Savona MR. Leveraging JAK-STAT regulation in myelofibrosis to improve outcomes with allogeneic hematopoietic stem-cell transplant. Ther Adv Hematol. 2018;9(9):251-259.
Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-862.
Hu X, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):1-33.
Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4): 374-384.
Säemann MD, Böhmig GA, Österreicher CH, et al. Suppression of primary T-cell responses and induction of alloantigen-specific hyporesponsiveness in vitro by the Janus kinase inhibitor tyrphostin AG4901. Transplantation. 2000;70(8):1215-1225.
Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosisruxolitinib in myelofibrosis. Clin Cancer Res. 2012;18(11): 3008-3014.
Raedler LA. Jakafi (Ruxolitinib): first FDA-approved medication for the treatment of patients with polycythemia vera. Am Health Drug Benefits. 2015;8(Spec Feature):75.
Yang W, Zhu G, Qin M, et al. The effectiveness of ruxolitinib for acute/chronic graft-versus-host disease in children: a retrospective study. Drug Des Devel Ther. 2021;15:743-752.
Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs. 2017;77(18):1987-2001.
Zand MS. Tofacitinab in renal transplantation. Transplant Rev (Orlando). 2013;27(3):85-89.
Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479-e114.
Assadiasl S, Fatahi Y, Mosharmovahed B, Mohebbi B, Nicknam MH. Baricitinib: from rheumatoid arthritis to COVID-19. J Clin Pharmacol. 2021;61(10):1274-1285.
Choi J, Cooper ML, Staser K, et al. Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia. 2018;32(11):2483-2494.
Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019;8:212595.
Spinelli FR, Meylan F, O'Shea JJ, Gadina M. JAK inhibitors: ten years after. Eur J Immunol. 2021;51(7):1615-1627.
Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am J Clin Dermatol. 2020;21(6):783-798.
Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4(5):e225-e236.
Garcia GG, Harden P, Chapman J. The global role of kidney transplantation. Kidney Blood Press Res. 2012;35(5):299-304.
Yang N, Luo M, Li R, et al. Blockage of JAK/STAT signalling attenuates renal ischaemia-reperfusion injury in rats. Nephrol Dial Transplant. 2008;23(1):91-100.
Si Y, Bao H, Han L, et al. Dexmedetomidine protects against renal ischemia and reperfusion injury by inhibiting the JAK/STAT signaling activation. J Transl Med. 2013;11(1):1-12.
O'Connell S, Tuite N, Slattery C, Ryan MP, McMorrow T. Cyclosporine A-induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2011;126(1):101-113.
Neria F, Castilla MA, Sanchez RF, et al. Inhibition of JAK2 protects renal endothelial and epithelial cells from oxidative stress and cyclosporin A toxicity. Kidney Int. 2009;75(2):227-234.
Borie DC, Changelian PS, Larson MJ, et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation. 2005;79(7):791-801.
Paniagua R, Si M-S, Flores MG, et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation. 2005;80(9):1283-1292.
Stepkowski SM, Kao J, Wang M-E, et al. The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. J Immunol. 2005;175(7):4236-4246.
Van Gurp E, Weimar W, Gaston R, et al. Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant. 2008;8(8):1711-1718.
Quaedackers ME, Mol W, Korevaar SS, et al. Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients. Transplantation. 2009;88(8):1002-1009.
van Gurp EA, Schoordijk-Verschoor W, Klepper M, et al. The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients. Transplantation. 2009;87(1):79-86.
Busque S, Leventhal J, Brennan D, et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant. 2009;9(8):1936-1945.
Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010;53(24):8468-8484.
Lamba M, Tafti B, Melcher M, Chan G, Krishnaswami S, Busque S. Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. Ther Drug Monit. 2010;32(6):778-781.
Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719-730.
Vincenti F, Tedesco Silva H, Busque S, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012;12(9):2446-2456.
Vincenti F, Silva H, Busque S, et al. Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patients. Am J Transplant. 2015;15(6):1644-1653.
Busque S, Vincenti FG, Tedesco Silva H, et al. Efficacy and safety of a tofacitinib-based immunosuppressive regimen after kidney transplantation: results from a long-term extension trial. Transplant Direct. 2018;4(9):e380.
Rovira J, Ramírez-Bajo MJ, Banon-Maneus E, et al. Tofacitinib halts progression of graft dysfunction in a rat model of mixed cellular and humoral rejection. Transplantation. 2018;102(7):1075-1084.
Nakamura K, Oshima S, Maeda M, et al. Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates. Int Immunopharmacol. 2018;64:201-207.
Nakamura K, Kawato Y, Kaneko Y, et al. Prevention of chronic renal allograft rejection by AS2553627, a novel JAK inhibitor, in a rat transplantation model. Transpl Immunol. 2018;46:14-20.
Chen F, Zou Y, Wang J, Huang C. Bone marrow mesenchymal stem cells (BMSCs)-exosomes carrying MicroRNA-965 attenuates allogeneic renal transplant rejection through regulation of janus kinase/signal transducers and activators of transcription 3 (JAK/STAT3). J Biomater Tissue Eng. 2022;12(8):1542-1549.
Kim I-C, Youn J-C, Kobashigawa JA. The past, present and future of heart transplantation. Korean Circ J. 2018;48(7):565-590.
Bulcao CF, D'Souza KM, Malhotra R, et al. Activation of JAK-STAT and nitric oxide signaling as a mechanism for donor heart dysfunction. J Heart Lung Transplant. 2010;29(3):346-351.
Stepkowski S, Zhang Y, Furian L, et al. STAT5A/B control survival of t cells by regulating the function of pro-and anti-apoptotic genes during allograft rejection. Transplantation. 2004;78(2):549-550.
Behbod F, Erwin-Cohen RA, Wang M-E, et al. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol. 2001;166(6):3724-3732.
Stepkowski SM, Erwin-Cohen RA, Behbod F, et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood. 2002;99(2):680-689.
Deuse T, Velotta JB, Hoyt G, et al. Novel immunosuppression: R348, a JAK3-and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation. 2008;85(6):885-892.
Deuse T, Hua X, Taylor V, et al. Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545. Transplantation. 2012;94(7):695-702.
Nakamura K, Inami M, Morio H, et al. AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts. Eur J Pharmacol. 2017;796:69-75.
Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302(5646):875-878.
Zhang M, Xu M, Wang K, Li L, Zhao J. Effect of inhibition of the JAK2/STAT3 signaling pathway on the Th17/IL-17 axis in acute cellular rejection after heart transplantation in mice. J Cardiovasc Pharmacol. 2021;77(5):614.
Rousvoal G, Si MS, Lau M, et al. Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Transpl Int. 2006;19(12):1014-1021.
Assadiasl S, Nicknam MH. Cytokines in lung transplantation. Lung. 2022;200(6):793-806.
Higuchi T, Shiraishi T, Shirakusa T, et al. Prevention of acute lung allograft rejection in rat by the janus kinase 3 inhibitor, tyrphostin AG490. J Heart Lung Transplant. 2005;24(10):1557-1564.
Muffak-Granero K, Olmedo C, Garcia-Alcalde F, et al. Gene network profiling before and after transplantation in alcoholic cirrhosis liver transplant recipients. Transplantation Proceedings; 2012;44(6):1493-1495.
Westbrook RH, Lea NC, Mohamedali AM, et al. Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation. Liver Transpl. 2012;18(7):819-827.
Freitas MCS, Uchida Y, Zhao D, Ke B, Busuttil RW, Kupiec-Weglinski JW. Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusion. Liver Transpl. 2010;16(5):600-610.
Jia L, Wang F, Gu X, et al. Propofol postconditioning attenuates hippocampus ischemia-reperfusion injury via modulating JAK2/STAT3 pathway in rats after autogenous orthotropic liver transplantation. Brain Res. 2017;1657:202-207.
Meunier L, Clerc C, Meszaros M. Use of tofacitinib for ulcerative colitis in a liver transplant patient. J Crohns Colitis. 2021;15(4):695-695.
Dold L, Lutz P, Heine A, Weismüller TJ, Strassburg CP, Spengler U. Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation. Clin Case Rep. 2021;9(9):e04782.
He K, Xu S, Shen L, Chen X, Xia Q, Qian Y. Ruxolitinib as adjunctive therapy for hemophagocytic lymphohistiocytosis after liver transplantation: a case report and literature review. J Clin Med. 2022;11(21):6308.
Perri R, Assi M, Talwalkar J, et al. Graft vs. host disease after liver transplantation: a new approach is needed. Liver Transpl. 2007;13(8):1092-1099.
Endo Y, Oshima G, Hibi T, et al. Achievement of durable and complete remission of graft-versus-host disease after liver transplantation with ruxolitinib: a case report. Transplantation. 2019;103(11):e375-e377.
Jacobs MT, Olson M, Ferreira BP, et al. The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation. Am J Transplant. 2020;20(2):589-592.
Kakadia S, Trotta H, Kurczek L, Burdine L, Veeraputhiran M, Giorgakis E. Early outcomes of ruxolitinib in the treatment of steroid refractory graft-versus-host disease on liver transplant recipients. Transplantation. 2020;104(8):e247.
Ahmad MI, Abughazaleh S, Kodali S, Schwartz MR. S2390 graft vs host disease (GVHD) in post liver transplant patient successfully treated with ruxolitinib. Official Journal of American college of Gastroenterol. 2020;115:S1270.
Kim E, Adeel A, Bozorgzadeh A, et al. Treatment of acute graft-versus-host disease in liver transplant recipients. Case Rep Transplant. 2021;2021:8981429.
Ghobrial S, Gonzalez C, Yazigi N, et al. Efficacy and feasibility of ruxolitinib in chronic steroid-refractory GVHD in a pediatric intestine transplant. Pediatr Transplant. 2021;25(3):e13836.
Brunet M. Cytokines as predictive biomarkers of alloreactivity. Clin Chim Acta. 2012;413(17):1354-1358.
Assadiasl S, Mooney N, Nicknam MH. Cytokines in liver transplantation. Cytokine. 2021;148:155705.
Khoo JK, Barnes H, Key S, Glaspole IN, Östör AJ. Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis. Rheumatology (Oxford). 2020;59(9):2217-2225.
Verden A, Dimbil M, Kyle R, Overstreet B, Hoffman KB. Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf. 2018;41:357-361.
Hoisnard L, Lebrun-Vignes B, Maury S, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022;12(1):7140.